Logo web

2010 Survey: Life Sciences Industry Outlook
Required Required Question(s)
Required 1.

Your survey responses will be kept anonymous and confidential, but we ask for the following information for quality control purposes:
First Name:
Last Name:
Company Name:
Email Address:
emailaddress@xyz.com

Required 2.

Which of the following best describes your current role or employer:
Life sciences company (public)
Life sciences company (private)
Buy-side (portfolio manager, analyst, partner, etc.)
Sell-side research analyst/director
Venture capitalist
Investment banker
Service provider (other)
Required 3.

Are you (or your company) in San Francisco, California, between January 11-14, 2010, for meetings in connection with the JP Morgan Healthcare Conference?
Yes
No
Undecided at this point
4.


If you answered "no" to Question #3, please select the single most important factor that affected your decision not to attend:
Conservation of capital, too expensive to attend (travel, hotel, etc.)
Attended in the past, but didn't find meeting(s) productive
Scheduling conflict prevents me from attending, otherwise would be there
Have not attended meeting in the past, unsure of benefit
Prefer to attend the BIO CEO & Investor Conference in NY during February 2010
Other  
Required 5.

In terms of raising visibility and capital, what is the single greatest challenge facing most life sciences companies in 2010?
General risk aversion in the financial markets
Average market capitalization of companies too small and/or lack of liquidity
Clinical or regulatory uncertainty as it relates to the FDA
Intellectual property concerns (eg, generic biologics, patent reform, etc.)
Stage of development too early
Healthcare reform legislation
Lack of experienced management talent pool
Other  
Required 6.


In terms of access to capital for most life sciences companies, what is your outlook for 2010?
Negative, access to capital will deteriorate
Neutral, access to capital will be about the same as 2009
Favorable, access to capital will improve modestly year-over-year
Very favorable, access to capital will improve markedly with IPO's possible
Required 7.

For 2010, how should life sciences companies manage their level of activity with investors and analysts?
 Reduce Activity Maintain Historical Activity Increase Activity   
Management presentation(s) at investor conferences   
Quarterly management update teleconferences   
One-on-one meetings with management (eg, non-deal roadshows)   
Website, email, and other electronic communications   
Conduct an analyst or R&D day   
Required 8.

In terms of raising capital and/or business development activity, which key therapeutic area do you expect to attract the most interest/visibility during 2010?
Oncology (solid tumors)
Oncology (hematological malignancies)
Metabolic disorders (eg, diabetes, obesity)
Cardiovscular
Central nervous system disorders (eg, Parkinson's disease)
Infectious disease
Supportive care (eg, pain management)
Dermatologicals
Genito-urinary & sex hormones
Other  
Required 9.


Do you expect merger & acquisition activity to accelerate in 2010 (compared to 2009)?
Yes
No
Required 10.


In terms of company and/or industry news, updates, and other information, which of the following do you regularly utilize?
 Never Some of the time Most of the time All of the time  
Company website  
Email subscription/RSS feed  
Investor websites (eg, Seeking Alpha, TheStreet.com, etc.)  
Industry portals/blogs (eg, BioSpace, Beck on Biotech, etc.)  
Twitter  
Facebook  
LinkedIn  
11.

Optional - If you would like to provide a brief quote that will be attributed to you when the results of this survey are published/presented publicly, please feel free to enter it below.  This could be advice that you would offer to others, additional color regarding your 2010 outlook,  etc.  (note - the rest of your survey responses remain confidential, only this quote may be disclosed):
 

  • 350 characters left.